Advantages of continuous manufacturing for pharma

Continuous manufacturing forms part of the industry 4.0 paradigm, and following success in other sectors this approach is being applied to pharmaceuticals moving from batch manufacturing to continuous manufacturing. The company Debut Bio has announced their seed funding of $2.6 million, with KdT Ventures leading. The round was oversubscribed and included participation from Better Ventures, FTW Ventures, and SpringTide Ventures. Debut Bio helps the pharmaceutical and specialty chemical industries manufacture high value molecules by combining custom-designed immobilized enzymes with continuous biomanufacturing processes. The company’s cell-free platform has the ability to transform low-value bio-renewable materials like glucose into high value therapeutics and specialty chemicals.